Health-related quality of life (HRQoL) of pembrolizumab (pembro) versus physician choice single-agent paclitaxel, docetaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma (ACC) or squamous cell carcinoma (SCC) of the esophagus that has progressed after first-line standard therapy (KEYNOTE-181)
Adenis, A Kulkarni, A Girotto, GC De La Fouchardiere, C Senellart, H van Laarhoven, HWM Hochhauser, D Mansoor, Was Al-Rajabi, R Norquist, J
Adenis, A
Kulkarni, A
Girotto, GC
De La Fouchardiere, C
Senellart, H
van Laarhoven, HWM
Hochhauser, D
Mansoor, Was
Al-Rajabi, R
Norquist, J
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Adenis A, Kulkarni A, Girotto GC, De La Fouchardiere C, Senellart H, Van Laarhoven HWM, et al. Health-related quality of life (HRQoL) of pembrolizumab (pembro) versus physician choice single-agent paclitaxel, docetaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma (ACC) or squamous cell carcinoma (SCC) of the esophagus that has progressed after first-line standard therapy (KEYNOTE-181). J Clin Oncol. 2019;37(15_suppl):4048-.